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The authors of this text should be applauded for aiming to provide
a comprehensive chemotherapy protocol book and easy reference
text for the practicing oncologist. Do they achieve their goal? They
have certainly provided a broad compilation of the majority of
commonly used chemotherapy protocols for malignant disease,
which will serve as a good reference text in oncology departments.
The book has an interesting and unusual style and format. There
is a short introductory section entitled ￿General Principles￿, which
covers supportive therapy, and toxicity and administration guide-
lines. I found this section suffered from being too brief. The authors
should have been able to cover toxicity and administration for all
the commonly used cytotoxic drugs in some detail. In the
supportive therapy section, there are some idiosyncrasies of treat-
ment with which I would not necessarily agree. Unfortunately,
because the book is not referenced in the conventional way, it is not
possible to access the source easily and examine the evidence for
the guidelines. For example, in the treatment of extravasation of
vesicant cytotoxic drugs, the authors suggest using 99% dimethyl
sulphoxide four times daily for 2 weeks and reference a random-
ized study in rats. These recommendations would certainly not be
current standard practice in oncology centres, but if it is true, we
need to see the evidence for it so that improvements in practice can
be introduced. For the commonly used drugs some important infor-
mation is emphasized, which will guide good clinical practice, but
in my view, this section should have been more comprehensive.
The main section of the book itemises the majority of protocols
used over the past 25 years. In the larger chapters (e.g. on breast
cancer) it is difficult to discover how the protocols have been
ordered, although the sequence seems to be more or less chrono-
logical. It would be helpful to know whether there is anything
more significant about the order in which the protocols are
presented, because it would enable the reader to give some sort of
￿weighting￿ to each. The comments sections are on the whole very
useful, giving information on response rates and some important
comparisons with other protocols, together with a reference for
each protocol.
There are some inaccuracies and omissions. For example, the
AC regimen listed for breast cancer is not the one that most prac-
ticing oncologists would recognize or frequently use. The single
agent activities listed at the beginning of each chapter are useful
but, unfortunately, some contain inaccuracies, e.g. to ascribe
cisplatinum a single agent response rate of only 27% in ovarian
cancer is incorrect. In the section on osteosarcomas in protocols
using high-dose methotrexate, the folinic acid rescue regimens are
unclear and, despite the fact this is covered in the introductory
section, this is of such importance that I think it should be empha-
sized within each protocol using high-dose methotrexate. In the
section on Ewing￿s sarcoma, the now commonly used IVAD/IVA
and EVAIA protocols are not included — which they should be for
this rare tumour. There are some inaccuracies in the section on
non-small-cell lung cancer, soft tissue sarcomas and osteosarcoma
which could be a little more serious if attempts were made to
implement them by practicing oncologists. Discrepancies between
this book and the clinical papers it cites could lead patients to be
over- or under-treated.
As a comprehensive reference book and short guide to the
majority of chemotherapy protocols, this book works well enough
and will find a place as a reference book in oncology pharmacies
and oncology libraries, and on the shelves of practicing oncolo-
gists. However, despite the disclaimer by the authors and
publishers at the start, the inaccuracies that it contains should be
addressed.
Helena Earl
Oncology Centre
University of Cambridge 
Box 193 Addenbrooke's Hospital
Hills Road
Cambridge CB2 2QQ
Lung Cancer, Second Edition
Edited by JA Roth, JD Cox and WK Hong, Publication
Details: Price £75.00, ISBN 0–86542–573–6. Blackwell
Science: UK, 1998.
This book is the second edition of a book which aims to cover all
aspects of lung cancer. It has been updated over the last 5 years
and edited by authors from the MD Anderson Cancer Centre,
Texas, USA.
This book would aim to pitch itself as an intermediate work of
reference, i.e. it should be a source of information more detailed
than a general oncology textbook but fall short of the most recent
advances in lung cancer which by their very nature would have to
be published in peer reviewed journals. There are 20 chapters that
cover most areas of lung cancer. A large number of chapters focus
on developing strategies in lung cancer such as molecular and
fluorescent detection, chemoprevention, lung cancer genetics and
growth factor and biologic approaches to therapy. The more stan-
dard treatment modalities for lung cancer, such as surgery, radio-
therapy and chemotherapy, are covered but there are some notable
omissions which will be discussed later.
The early chapters include the biology of pre-neoplastic
regions, and give a very detailed and good historical background
to the subject. In particular, there is a good summary of the
chromosomal abnormalities present and some discussion on how
multistage carcinogenesis may apply in this disease. The chapter
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to the subject, but illustrates the point that there are as yet no
known susceptibility genes.
The next three chapters discuss recent advances in surgery.
There is an excellent overview of preoperative evaluation for
patients requiring surgery. Although the described preoperative
work-up of a patient requiring lung cancer surgery is more elabo-
rate than one would expect for a UK practice, it is becoming
apparent that patients will require a more detailed estimation of
their lung function prior to surgery and this is well described. It
was pleasing to read that the authors are against segmental resec-
tion, as most practitioners in this field would feel that a lobectomy
would be the minimum required operation. There is an increasing
role for keyhole thorascopic surgery in the diagnosis and treatment
of lung cancer, and the chapter by Lo Cicero III again gives a
balanced view of the do￿s and don￿ts of video-assisted thoracic
surgery (VATS). It discusses the very difficult problem regarding
sampling of the subcarinal node station. However, Lo Cicero III
does fall short of discussing the very useful application of VATS in
the treatment of effusions and a diagnosis of mesothelioma. There
is a small, but definite, place for surgery for small-cell lung cancer
and this is nicely described. The role of surgery should probably
be limited to those patients with true stage I disease who have been
fully assessed prior to surgery.
The role of radiotherapy is discussed in three chapters. The first
deals with endobronchial brachytherapy and highlights the
problem that we do not really know enough about this modality to
be sure of its place within the therapeutic armamentarium. It
would probably prove useful in recurrent disease previously
treated with external beam radiotherapy, and possibly as a boost
for patients treatable with radical radiotherapy. Some of the illus-
trations in this section leave much to be desired and are of poor
quality. The next chapter deals with conformal and three-
dimensional radiotherapy. It suffers from the fact that there are no
randomized trial data. Probably one of the most major omissions
in the book is that there is no mention of altered fractionation
and, in particular, Continuous Hyperfractionated Accelerated
Radiotherapy (CHART). This treatment has been shown in a
randomized trial to confer a 9% absolute survival benefit and is
one of the major advances in the treatment of NSCLC in recent
years. Indeed, the next chapter on concurrent chemotherapy and
radiation has been shown to confer only very marginal advances
over conventional radiotherapy but merits its own chapter.
The chapter on pre- and post-operative adjunctive therapy in
resectable NSCLC is perhaps surprisingly short given the intense
amount of controversy in this area. The oft quoted studies of
Rosell and Roth are mentioned only briefly and not discussed in
any great detail. In particular, it is noticeable that the reference for
Roth relates to an abstract rather than the definitive paper which
has been in general circulation for many years. The results of the
MRC meta-analysis of post-operative radiotherapy (PORT) were
published too late for inclusion in this book but would make an
interesting addition. It also proposes a new staging for stage III
disease but it is interesting to note that it does not take into account
the revised classification by Mountain in 1997 where T3 N0
tumours are now stage IIB. The authors of this chapter would wish
them to be described as stage III1.
The many new agents available for treating NSCLC are
described in great detail and as most of these studies are phase II
they concentrate purely on response rates. It is also of note that
most of the phase III studies do not show any improvement in
median survival for stage IIIB and IV disease. One omission,
which will become less tolerated in the oncological community as
a whole, is the requirement to include quality of life data in evalu-
ating these new agents.
The emerging therapies of chemoprevention and photodynamic
therapy are discussed, but their clinical relevance remains uncer-
tain. Other major omissions in this book include no mention of the
role of PET scanning in N2 and metastatic disease. The manage-
ment of small-cell lung cancer, although taking a back seat
compared to new studies in NSCLC, does deserve some mention.
In particular, discussion of new agents both chemotherapeutic
and anti-angiogenic. The role of prophylactic cranial irradiation
(PCI) should be discussed in the light of new trials and a meta-
analysis.
All in all this book would be a useful addition to an oncology
department library and is essential reading for the sub-specialist. I
would therefore recommend its purchase to those categories, but I
feel it does not warrant wider purchase.
David Gilligan
Papworth Hospital NHS Trust
Papworth Everard
Cambridge CB3 8RE
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